Ask about this productRelated genes to: TMEM173 antibody
- Gene:
- TMEM173 NIH gene
- Name:
- transmembrane protein 173
- Previous symbol:
- -
- Synonyms:
- FLJ38577, NET23, ERIS, MPYS, STING, MITA
- Chromosome:
- 5q31.2
- Locus Type:
- gene with protein product
- Date approved:
- 2006-08-24
- Date modifiied:
- 2019-04-23
Related products to: TMEM173 antibody
Related articles to: TMEM173 antibody
- The innate immune signaling pathway cGAS-STING plays an important role in the recognition of cytosolic nucleic acids and the induction of the interferon-dependent antiviral response. Despite the significant research interest in this cascade in the context of immune system function, the mechanisms regulating cGAS-STING signaling and the switch between its pro-inflammatory and pro-apoptotic effects remain largely underexplored. According to publicly available RNA-seq data and microarray analyses, SETD7 lysine methyltransferase participates in interferon signaling in cancer cells. This study aims to elucidate the role of SETD7 in the regulation of the STING-dependent immune response in human lung adenocarcinoma (LUAD) cells. For this purpose, we developed a reproducible and cost-effective method for inducing the STING cascade by transfecting cells with salmon sperm DNA (sspDNA). We demonstrated that sspDNA efficiently induces phosphorylation of the key components of the STING-TBK1-IRF3 signaling pathway and activates the expression of interferons and pro-inflammatory cytokines. Using this approach, we further demonstrated that SETD7 is involved in the regulation of the IRF3-dependent transcriptional program. Suppression of SETD7 was associated with changes in the expression of genes related to innate immune response and apoptosis, including increased levels of , , , (PUMA), and . Furthermore, attenuation of SETD7 expression reduced the lentiviral transduction efficacy in H1299 cells. These results suggest that SETD7 may play a role in regulating the switch in STING signaling between pro-inflammatory and pro-apoptotic responses in LUAD cells. - Source: PubMed
Publication date: 2026/04/30
Nevzorov Ivan AKorableva PolinaShuvalov OlegParfenyev SergeyBarlev Nickolai ADaks Alexandra - Glioblastoma (GBM) remains one of the most lethal brain malignancies because of its highly immunosuppressive tumor microenvironment and the limited penetration of therapeutics across the blood-brain barrier (BBB). Although recent studies have separately explored STING agonism, microglial reprogramming, and nanocarrier-based drug delivery, an integrated framework combining these strategies for GBM immunotherapy is still lacking. In this review, we present a new dual-function lipid-based nanovector (LNV) strategy that simultaneously activates the cGAS-STING pathway and induces tumor-associated microglia to repolarize toward the antitumor M1 phenotype. In contrast to previous reviews, which address them as individual approaches, herein we consolidate these into an integrated therapeutic paradigm and provide a rational design roadmap based on drug cargo selection, lipid isoform composition, BBB targeting, and thermo-/magnetically responsive release. We summarize how STING activation enhances type I interferon signaling, dendritic cell maturation, and cytotoxic T-cell priming, while M1-polarized microglia potentiate local inflammatory and phagocytic antitumor responses. In addition, we summarize the current nanocarrier platforms, preclinical evidence, and translational design considerations pertinent to this combinatorial approach. This review provides a conceptually integrated overview of the potential of dual-action lipid nanovectors to overcome clinically relevant immunological and delivery barriers in GBM, as well as future directions for next-generation nano-immunotherapies. - Source: PubMed
Nafie Mohamed SDiab Mohamed KhaledFahmy Sherif Ashraf - IgAN is a common primary glomerular disease, and age may affect its clinical manifestations and progression. However, age-related differences in elderly IgAN, especially the role of podocyte senescence and the cGAS-STING pathway in elderly IgAN patients, remain incompletely understood. - Source: PubMed
Publication date: 2026/05/04
Cai YanYang YanYuan YuanJiang XueZhao Shuman - Large extracellular vesicles (EVs) derived from tumour cells play important roles in tumour formation and progression. However, it remains unclear why malignant cells produce these EVs and how they act in vivo. We employ a well-characterized Drosophila tumour model and demonstrate that large EV biogenesis from malignant cells is an evolutionarily conserved process. Our study uncovers an essential role for the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, which mediates the innate immune response to cytosolic DNA, in driving large EV biogenesis and inducing a systemic immune response to tumours. STING engages a signalling axis comprising JNK and FAK-independent of TANK-binding kinase 1 (TBK1) and inhibitor of nuclear factor κB kinase (IKKβ)-to drive large EV biogenesis in both Drosophila and human malignant cells. Transplantation of large EVs from Drosophila tumours to wild type larvae is sufficient to recapitulate the systemic immune response to tumours by activating STING signalling in macrophage-like cells. Thus, our study establishes a novel animal model for studying large EVs derived from malignant cells and provides insights into how STING signalling propagates from tumour cells to the immune system via large EV biogenesis, inducing a systemic immune response to tumours. - Source: PubMed
Lee JiaeVernon AnnabelPark Hyung JoonKwon Young V - The cGAS-STING signaling pathway is a crucial component of the innate immune system that detects aberrant cytosolic DNA, such as that derived from viruses or damaged cells, to activate downstream immune responses. Within this pathway, cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) serves as the essential second messenger linking DNA sensing to immune activation. Upon recognition of cytosolic DNA, cGAS synthesizes cGAMP, whose unique "mixed linkage" structure enables efficient binding to and activation of the STING protein on the endoplasmic reticulum, thereby inducing type I interferons and inflammatory cytokines. This review details cGAMP's biosynthesis, structural characteristics, and transport mechanisms, including efflux via ABCC1 and uptake by SLC19A1, underscoring its role as an intercellular "immune messenger." It also explores the dual functions of cGAMP in antiviral and antitumor immunity as well as in autoimmune and aging-related diseases, where it can either enhance immune defense or promote chronic inflammation. Therapeutically, cGAMP has been investigated as a vaccine adjuvant, a target for synthesis or degradation enzymes, and in nanoparticle-based delivery systems. However, challenges regarding its stability, delivery efficiency, and immunotoxicity remain, and future research should focus on real-time monitoring and tissue-specific modulation to advance cGAMP-based precision immunotherapeutics. - Source: PubMed
Publication date: 2026/05/10
Dai ZhonglingMa ChenggongDing HuiqingFu LiyaoJiang HejunTai Shi